Amgen 1 mai 2026 Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data - Fierce Biotech
Amgen 29 avr. 2026 Amgen, AstraZeneca join FDA effort harnessing cloud for real-time clinical trials - BioSpace
Amgen 28 avr. 2026 FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board - Fierce Biotech
Amgen 28 avr. 2026 FDA turns up heat on Amgen, proposing to rescind approval of Tavneos - Fierce Pharma
Amgen 24 avr. 2026 Amgen’s Chief Technology Officer Dr David Reese to retire - European Pharmaceutical Review
Amgen 20 avr. 2026 Zurcher Kantonalbank Zurich Cantonalbank Buys 55,333 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen 16 avr. 2026 Federal Circuit Distinguishes Amgen in Reversal of Invalidation of Teva Headache Treatment Patents - IPWatchdog.com
BioPharma Dive 6 avr. 2026 Under-the-skin Tepezza comparable to infused version in key study, Amgen says
Endpoints News 6 avr. 2026 Amgen seeks to buoy Tepezza with injectable data in face of incoming competition